肿瘤溶解综合征

Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3-11.

• 全文
• 摘要

Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med. 1993;94:133-139.

• 摘要

Montesinos P, Lorenzo I, Martin G, et al. Tumour lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93:67-74.

• 全文
• 摘要

Mughal TI, Ejaz AA, Foringer JR, et al. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev. 2010;36:164-176.

• 摘要

Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-554.

• 摘要

Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767-2778.

• 摘要

Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844-1854.

• 摘要

Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Francaise d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol. 2002;13:789-795.

• 全文
• 摘要

1.  Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3-11.

• 全文
• 摘要

2.  Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med. 1993;94:133-139.

• 摘要

3.  Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma. 2003;44:77-83.

• 摘要

4.  Montesinos P, Lorenzo I, Martin G, et al. Tumour lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93:67-74.

• 全文
• 摘要

5.  Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone - results of a multicenter phase III study. J Clin Oncol. 2010;28:4207-4213.

• 摘要

6.  Mughal TI, Ejaz AA, Foringer JR, et al. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev. 2010;36:164-176.

• 摘要

7.  Nicholaou T, Wong R, Davis ID. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet. 2007;369:1923-1924.

• 摘要

8.  McCroskey RD, Mosher DF, Spencer CD, et al. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer. 1990;66:246-250.

• 摘要

9.  Cany L, Fitoussi O, Boiron JM, et al. Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma. J Clin Oncol. 2002;20:2212.

• 摘要

10.  Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol). 2006;18:773-780.

• 摘要

11.  Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors - a case report and review of the literature. Cancer Chemother Pharmacol. 2003;51:187-192.

• 摘要

12.  Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206-212.

• 摘要

13.  Jeha S. Tumor lysis syndrome. Semin Hematol. 2001;38:4-8.

• 摘要

14.  Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-554.

• 摘要

15.  Michallet AS, Tartas S, Coiffier B. Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Support Cancer Ther. 2005;2:159-166.

• 摘要

16.  Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767-2778.

• 摘要

17.  Mato AR, Riccio BE, Qin L, et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma. 2006;47:877-883.

• 摘要

18.  Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol. 2004;130:623-625.

• 摘要

19.  Habib GS, Saliba WR. Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Am J Med Sci. 2002;323:155-157.

• 摘要

20.  Fer MF, Bottino GC, Sherwin SA, et al. Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon. Am J Med. 1984;77:953-956.

• 摘要

21.  Simmons ED, Somberg KA. Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer. 1991;67:2062-2065.

• 摘要

22.  Pession A, Barbieri E. Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica. Contrib Nephrol. 2005;147:80-92.

• 摘要

23.  Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008;93:1877-1885.

• 全文
• 摘要

24.  Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr. 1986;109:292-298.

• 摘要

25.  Hande KR, Hixson CV, Chabner BA. Postchemotherapy purine excretion in patients receiving allopurinol. Cancer Res. 1981;41:2273-2279.

• 全文
• 摘要

26.  Smalley RV, Guaspari A, Haase-Statz S, et al. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 2000;18:1758-1763 (erratum in: J Clin Oncol 2000;18:2188).

• 摘要

27.  Cheuk DK, Chiang AK, Chan CC, et al. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. Cochrane Databse Syst Rev. 2010;(6): CD006945.

• 全文
• 摘要

28.  Oldfield V, Perry CM. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. Drugs. 2006;66:529-546.

• 摘要

29.  Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol. 2001;38:13-21.

• 摘要

30.  Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844-1854.

• 摘要

31.  Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med.1980;68:486-491.

• 摘要

32.  Krakoff IH, Murphy ML. Hyperuricemia in neoplastic disease in children: prevention with allopurinol, a xanthine oxidase inhibitor. Pediatrics. 1968;41:52-56.

• 摘要

33.  Yarpuzlu A. A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta. 2003;333:13-18.

• 摘要

34.  Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 8: advanced challenges in resuscitation: section 1: life-threatening electrolyte abnormalities. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation. 2000;102:217-222.

• 全文
• 摘要

35.  Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Francaise d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol. 2002;13:789-795.

• 全文
• 摘要

36.  Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996;14:1252-1261.

• 摘要

37.  Hummel M, Buchheidt D, Reiter S, et al. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol. 2005;75:518-521.

• 摘要